Seroatlas · Human Serome Atlas

TNFRSF10C

Tumor necrosis factor receptor superfamily member 10C

Also known as: CD263, DcR1, LIT, TR10C_HUMAN, TRAILR3, TRID

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: O14798
Gene: TNFRSF10C
Ensembl: ENSG00000173535
Chromosome: 8
Canonical length: 259 aa
Protein class: Cancer-related genes, CD markers, Predicted membrane proteins

OverviewNCBI Gene

The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor contains an extracellular TRAIL-binding domain and a transmembrane domain, but no cytoplasmic death domain. This receptor is not capable of inducing apoptosis, and is thought to function as an antagonistic receptor that protects cells from TRAIL-induced apoptosis. This gene was found to be a p53-regulated DNA damage-inducible gene. The expression of this gene was detected in many normal tissues but not in most cancer cell lines, which may explain the specific sensitivity of cancer cells to the apoptosis-inducing activity of TRAIL. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

259 residues, UniProt reviewed canonical sequence.

>O14798|TNFRSF10C
     1  MARIPKTLKF VVVIVAVLLP VLAYSATTAR QEEVPQQTVA PQQQRHSFKG EECPAGSHRS
    61  EHTGACNPCT EGVDYTNASN NEPSCFPCTV CKSDQKHKSS CTMTRDTVCQ CKEGTFRNEN
   121  SPEMCRKCSR CPSGEVQVSN CTSWDDIQCV EEFGANATVE TPAAEETMNT SPGTPAPAAE
   181  ETMNTSPGTP APAAEETMTT SPGTPAPAAE ETMTTSPGTP APAAEETMIT SPGTPASSHY
   241  LSCTIVGIIV LIVLLIVFV

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against TNFRSF10C can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.54
Highest tissue expression: 22 nTPM

Expression across tissuesHPA

Tissue

appendix: 22 nTPM
bone marrow: 20 nTPM
spleen: 17 nTPM
gallbladder: 12 nTPM
placenta: 7.8 nTPM
adipose tissue: 7.7 nTPM

Single-cell type

neutrophils: 209 nCPM
neutrophil progenitors: 26 nCPM
transitional alveolar cells: 3.6 nCPM
enterocytes: 3.3 nCPM
hofbauer cells: 3.3 nCPM
fallopian secretory cells: 2.9 nCPM

Immune cell

neutrophil: 3,205 nTPM
eosinophil: 512 nTPM
basophil: 58 nTPM
classical monocyte: 27 nTPM
non-classical monocyte: 22 nTPM
intermediate monocyte: 14 nTPM

Brain region

cerebral cortex: 5.3 nTPM
choroid plexus: 3.8 nTPM
medulla oblongata: 3.7 nTPM
pons: 3.6 nTPM
thalamus: 3.6 nTPM
spinal cord: 3.3 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.8
gnomAD pLI: 0
gnomAD missense Z: 0.82
DepMap mean gene effect: 0.02
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads TNFRSF10C as an antibody target. Whether an autoantibody or antibody against TNFRSF10C could matter depends on whether native TNFRSF10C is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

TNFRSF10C is annotated at the cell surface, where native TNFRSF10C is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label TNFRSF10C as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...